Mir A. Imran
Known title: DirectorCIK: 0001031686
Mir A. Imran's purchase track record
Mir A. Imran has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 7/21/2026 | RANI | $25K | pending | pending | — |
| 10/23/2025 | RANI | $1.26M | -33.5% | -56.2% | +5.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| RANI | ▲ Buy | Open Market | 36,000 | $25K | 7/21/2026 | View on chart |
| RANI | ▲ Buy | Open Market | 2,083,334 | $1.3M | 10/23/2025 | View on chart |
| RANI | ▼ Sell | Other | 7,694 | $0 | 8/23/2022 | View on chart |
| RANI | ▼ Sell | Other | 7,694 | $0 | 8/23/2022 | View on chart |
| RANI | ▼ Sell | Open Market | 71,042 | $747K | 8/17/2022 | View on chart |
| RANI | ▼ Sell | Open Market | 9,210 | $107K | 8/17/2022 | View on chart |
| RANI | ▼ Sell | Other | 2,309,490 | $0 | 3/7/2022 | View on chart |
| RANI | ▼ Sell | Other | 2,309,490 | $0 | 3/7/2022 | View on chart |
| RANI | ▼ Sell | Other | 2,229,238 | $0 | 3/7/2022 | View on chart |
| RANI | ▼ Sell | Other | 827,467 | $0 | 2/3/2022 | View on chart |
| RANI | ▼ Sell | Other | 67,707 | $0 | 2/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
RANI joins FDA Emerging Technology Platform
Rani Therapeutics was added to the FDA’s Emerging Technology Platform, a program that highlights innovative medical technologies. The inclusion signals that the FDA sees potential in the company’s approach and may facilitate future regulatory interactions. This development comes as the stock is trading near its recent support level.
RANI joins FDA Emerging Technology Platform. Rani Therapeutics was added to the FDA’s Emerging Technology Platform, a program that highlights innovative medical technologies. The inclusion signals that the FDA sees potential in the company’s approach and may facilitate future regulatory interactions. This development comes as the stock is trading near its recent support level.